drugset / Trial / NCT06592417
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
Timeline
- Start
- 2024-04-30
- Primary completion
- 2026-05-17
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JSKN016 | Unknown | 0.5 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | 1 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | 2 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | 4 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | 6 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | 7 mg/kg | Intravenous |
| Subject | JSKN016 | Unknown | 8 mg/kg | Intravenous |